New Non-Opioid Pain Drug Gets $11M to Fight Cancer Pain

Imagine getting life-saving chemotherapy, only to develop pain so severe you have to stop treatment. That's the reality for 40% of cancer patients, but a groundbreaking discovery could change everything.

Stony Brook University researchers have developed ART26.12, a first-of-its-kind pain medication that works completely differently from opioids or steroids. On March 27, California-based Artelo Biosciences announced it secured $11 million in private funding to push this innovative treatment toward FDA approval.

The drug targets chemotherapy-induced peripheral neuropathy (CIPN), a debilitating nerve pain that forces many cancer patients to reduce or abandon their treatments. Right now, no FDA-approved therapies exist for this condition, leaving patients with few options and difficult choices.

Professors Martin Kaczocha and Iwao Ojima discovered the compound by targeting fatty acid binding protein 5 (FABP5), essentially teaching the body to manage pain through its own lipid-signaling pathways. Unlike opioids, ART26.12 carries no addiction risk and has shown no adverse effects in early human trials.

The therapy showed profound pain reduction in preclinical testing and even helped patients tolerate chemotherapy better. Beyond cancer treatment, early research suggests it could help people suffering from diabetic neuropathy, nerve injuries, and osteoarthritis.

"This is not just another non-opioid therapy; it is a completely new strategy," said Gregory Gorgas, CEO of Artelo Biosciences. The company is the first and only one to bring a selective FABP5 inhibitor into human clinical testing.

More than 20% of Americans experience chronic pain annually, with neuropathic pain among the hardest to treat. The $11 million investment will fund the next phase of safety and efficacy studies to determine how well the therapy works in real clinical settings.

The Ripple Effect

This discovery represents more than just one new drug. It opens an entirely new pathway for pain management that could revolutionize treatment for generations to come.

Stony Brook licensed the technology to Artelo in 2018, showcasing how university research can transform into real-world solutions. The university's ecosystem of over 1,000 research faculty and 2,000 patents continues pushing innovation that delivers tangible public benefit.

For the millions managing chronic pain and the cancer patients forced to choose between treatment and unbearable nerve damage, this milestone brings genuine hope for safer, more effective relief.